GSK withdraws adult TD vaccine from Korea

Td-pur expires on November 30th

SK, which imports raw material, and GC Pharma, which are manufactured in Korea, compete with each other

Green Cross TD vaccine successfully localized in 2016

GSK will stop supplying the adult TD vaccine 'Td-pur', which was imported and sold in Korea.

 

The company said there was no additional import after November 30.

 

Until now, adult TD vaccines have been dependent on imports, but GC Pharma succeeded in localizing them in 2016.

 

With GSK's supply discontinuation of Td-pur, the localization of GC Pharma is in the limelight.

 

According to the MFDS, GSK announced the shutdown of the supply of TD-pur in July.

 

TD-pur is an adult TD vaccine.

 

It is a vaccine that prevents diphtheria and tetanus.

 

Four adult TD vaccines are licensed in Korea.

 

SK Td Vaccine Inj by SK Bioscience, Access Pharma's TD Booster SSI', 'Green Cross TD Vaccine PFS' by GC Pharma, and TD-pur by GSK have been competing.

 

Among them, the only domestic product is Green Cross TD Vaccine PFS.

 

It was approved for an adult TD vaccine made with its own technology in November 2016.

 

This product is regarded as a case of successful localization by receiving consulting support from the MFDS since 2010.

 

The MFDS at the time explained that the localization of the TD vaccine is expected to replace imports for 450,000 people every year.

 

SK TD vaccine is a product that is imported from GSK Germany and sold as a finished product in Korea.

 

In addition, DT Booster SSI is imported from Denmark SSI in finished form.

 

With the withdrawal of GSK TD-Pur in Korea, the market will now compete for these three items.

 

GSK said that it was unavoidable in the process of consolidating and overhauling the production line for business efficiency after the acquisition of Novartis Vaccine Division in 2015 due to the reason for the interruption of the supply of TD-Pur.

 

In Korea, competitiveness has also been lost since the launch of Green Cross TDI vaccine.

 

Last year, the sales of TD-Pur based on IQVIA amounted to about ￦300 million.

 

On the other hand, SK TD vaccine and Green Cross TD vaccine ranked first and second with ￦1.9 billion and ￦1.3 billion.

 

This year, the Green Cross TDI vaccine was ranked first for the first time.

 

The cumulative sales in the first half of the year were ￦600 million for Green Cross TD vaccine and ￦460 million for SK TD vaccine.

 

The domestic product has risen to the No.

 

1 market after 3 years of launch.

 

The localization of Green Cross TD vaccine is shining even more with the withdrawal of TD-Pur from GSK.

 

An industry insider said, "Since we can not guarantee a stable supply of imported vaccines as in this case of TD-Pur, there is no need to say the need for a domestic vaccine for the management of infectious diseases."